Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.